Latest news
VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - USA TodayUSA Today · Tue, 04 Aug 2026 04:28:55 GMTVeraxa Biotech (VRXA) grows patent estate for BiTAC cancer platforms - Stock TitanStock Titan · Fri, 31 Jul 2026 20:05:41 GMTVERAXA Biotech (VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC® Cancer Therapy Platform - NewMediaWireNewMediaWire · Thu, 30 Jul 2026 18:55:50 GMTVERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform - TradingViewTradingView · Thu, 30 Jul 2026 17:04:34 GMTVERAXA Biotech (VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform - Yahoo FinanceYahoo Finance · Thu, 30 Jul 2026 07:00:00 GMTVERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates - The Manila TimesThe Manila Times · Wed, 29 Jul 2026 11:20:51 GMTVERAXA filings expected to protect core tech through at least 2047 if granted - Stock TitanStock Titan · Wed, 29 Jul 2026 07:00:00 GMTBITAC job fair places over 50 trainees in employment - newagebd.netnewagebd.net · Wed, 29 Jul 2026 07:00:00 GMT